29.80
price down icon0.80%   -0.24
 
loading
Alkermes Plc stock is traded at $29.80, with a volume of 2.08M. It is down -0.80% in the last 24 hours and up +7.16% over the past month. Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
See More
Previous Close:
$30.04
Open:
$30.3
24h Volume:
2.08M
Relative Volume:
1.06
Market Cap:
$4.92B
Revenue:
$1.51B
Net Income/Loss:
$333.35M
P/E Ratio:
15.28
EPS:
1.95
Net Cash Flow:
$315.22M
1W Performance:
-1.52%
1M Performance:
+7.16%
6M Performance:
+7.70%
1Y Performance:
+10.99%
1-Day Range:
Value
$29.53
$30.51
1-Week Range:
Value
$29.53
$32.02
52-Week Range:
Value
$25.16
$36.45

Alkermes Plc Stock (ALKS) Company Profile

Name
Name
Alkermes Plc
Name
Phone
00-353-1-772-8000
Name
Address
CONNAUGHT HOUSE, DUBLIN 4
Name
Employee
1,800
Name
Twitter
@alkermes
Name
Next Earnings Date
2024-10-24
Name
Latest SEC Filings
Name
ALKS's Discussions on Twitter

Compare ALKS with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - Specialty & Generic icon
ALKS
Alkermes Plc
29.80 4.96B 1.51B 333.35M 315.22M 1.95
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
145.94 64.88B 9.39B 2.62B 2.22B 5.8121
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.01 44.40B 29.96B 957.25M 4.77B 0.2956
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.25 41.72B 14.26B 1.98B 2.47B 0.4327
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
18.95 21.82B 16.70B -157.13M 1.19B -0.1446
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
418.58 19.28B 3.08B 1.24B 1.07B 25.61

Alkermes Plc Stock (ALKS) Upgrades & Downgrades

Date Action Analyst Rating Change
Sep-26-25 Upgrade RBC Capital Mkts Sector Perform → Outperform
Sep-03-25 Initiated Wells Fargo Overweight
Jul-15-25 Initiated Goldman Buy
Jun-17-25 Upgrade UBS Neutral → Buy
May-28-25 Initiated Needham Buy
Mar-13-25 Initiated RBC Capital Mkts Sector Perform
Mar-04-25 Upgrade UBS Sell → Neutral
Feb-11-25 Initiated Deutsche Bank Buy
Nov-05-24 Upgrade Stifel Hold → Buy
Jun-17-24 Initiated TD Cowen Buy
Mar-19-24 Initiated Robert W. Baird Outperform
Feb-20-24 Downgrade UBS Neutral → Sell
Nov-20-23 Resumed JP Morgan Neutral
Oct-24-23 Upgrade Evercore ISI In-line → Outperform
Oct-17-23 Initiated UBS Neutral
Nov-03-22 Upgrade Piper Sandler Neutral → Overweight
Oct-14-22 Upgrade BofA Securities Underperform → Neutral
Aug-16-22 Initiated Piper Sandler Neutral
Apr-22-22 Resumed Goldman Buy
Apr-20-22 Initiated Goldman Buy
Jan-27-22 Upgrade Cantor Fitzgerald Hold → Overweight
Dec-01-21 Initiated Citigroup Neutral
Oct-07-21 Upgrade Jefferies Hold → Buy
Sep-02-21 Downgrade BofA Securities Neutral → Underperform
Oct-15-20 Upgrade Mizuho Neutral → Buy
Jul-30-20 Downgrade Goldman Neutral → Sell
Feb-14-20 Downgrade BofA/Merrill Buy → Neutral
Feb-14-20 Reiterated H.C. Wainwright Neutral
Feb-14-20 Downgrade JP Morgan Overweight → Neutral
Feb-06-20 Initiated Mizuho Neutral
Jan-31-20 Upgrade Wolfe Research Underperform → Peer Perform
Sep-05-19 Upgrade Morgan Stanley Underweight → Equal-Weight
Jul-15-19 Upgrade Goldman Sell → Neutral
May-31-19 Initiated H.C. Wainwright Neutral
May-01-19 Downgrade Citigroup Buy → Neutral
Dec-19-18 Downgrade Goldman Neutral → Sell
Dec-14-18 Initiated Wolfe Research Underperform
Dec-13-18 Downgrade Credit Suisse Outperform → Underperform
Nov-05-18 Initiated Piper Jaffray Neutral
Aug-07-18 Initiated Stifel Hold
Jun-21-18 Downgrade Morgan Stanley Equal-Weight → Underweight
Jun-06-18 Initiated B. Riley FBR, Inc. Buy
May-16-18 Upgrade Citigroup Neutral → Buy
May-11-18 Initiated BofA/Merrill Buy
View All

Alkermes Plc Stock (ALKS) Latest News

pulisher
12:04 PM

What recovery options are there for Alkermes plcWeekly Market Report & Safe Entry Point Alerts - newser.com

12:04 PM
pulisher
11:32 AM

Real time social sentiment graph for Alkermes plcAnalyst Upgrade & Capital Efficient Trading Techniques - newser.com

11:32 AM
pulisher
09:45 AM

3 Biopharma Names I Am Buying After Avadel's Buyout - Seeking Alpha

09:45 AM
pulisher
08:29 AM

Why Alkermes plc stock appeals to analysts2025 Macro Impact & AI Driven Stock Movement Reports - newser.com

08:29 AM
pulisher
07:46 AM

Is Alkermes plc (8AK) stock at risk of policy regulation2025 Winners & Losers & Detailed Earnings Play Strategies - newser.com

07:46 AM
pulisher
04:58 AM

Order flow analysis tools used on Alkermes plcMarket Growth Summary & AI Optimized Trade Strategies - newser.com

04:58 AM
pulisher
04:09 AM

Can Alkermes plc stock maintain growth trajectory2025 EndofYear Setup & Accurate Entry and Exit Point Alerts - newser.com

04:09 AM
pulisher
03:51 AM

Price momentum metrics for Alkermes plc explainedJuly 2025 PreEarnings & Reliable Intraday Trade Alerts - newser.com

03:51 AM
pulisher
03:18 AM

Can Alkermes plc stock deliver consistent earnings growthWeekly Risk Report & AI Forecast Swing Trade Picks - newser.com

03:18 AM
pulisher
Oct 25, 2025

Alkermes to Acquire Avadel, Adding LUMRYZ to Its Portfolio - Sleep Review

Oct 25, 2025
pulisher
Oct 24, 2025

Is Alkermes plc forming a bottoming baseTrade Risk Summary & Weekly High Return Stock Opportunities - newser.com

Oct 24, 2025
pulisher
Oct 24, 2025

Deal Dispatch: Four Roses, Quantum Computing, Travis KelceAir France (OTC:AFLYY), Alkermes (NASDAQ:ALKS) - Benzinga

Oct 24, 2025
pulisher
Oct 24, 2025

Biotech M&A Action Gets Another Jolt With $2 Billion Avadel-Alkermes Deal - TheStreet Pro

Oct 24, 2025
pulisher
Oct 24, 2025

Alkermes Plc expected to post earnings of 30 cents a shareEarnings Preview - TradingView

Oct 24, 2025
pulisher
Oct 24, 2025

Published on: 2025-10-24 02:21:47 - newser.com

Oct 24, 2025
pulisher
Oct 23, 2025

Published on: 2025-10-23 22:46:36 - newser.com

Oct 23, 2025

Alkermes Plc Stock (ALKS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Alkermes Plc Stock (ALKS) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Hopkinson Craig C.
EVP R&D, Chief Medical Officer
Oct 15 '25
Sale
31.53
9,000
283,776
73,740
$48.78
price up icon 0.60%
$22.05
price up icon 1.29%
$10.35
price up icon 0.39%
drug_manufacturers_specialty_generic RDY
$14.58
price down icon 0.27%
$144.00
price up icon 0.23%
$418.58
price down icon 1.79%
Cap:     |  Volume (24h):